Table 1.

The effect of L-AAA and Lu AA33810 administered alone or in combined treatment (A) and the effect of combined treatment of Lu AA33810 with the inhibitors of MAPK/ERK and PI3K signaling pathways (B) on the locomotor activity of rats

Treatment	Activity counts (5-min test)
A
Control	100.0 ± 8.61
L-AAA	118.4 ± 9.79
Lu AA33810	90.34 ± 7.04
L-AAA + Lu AA33810	127.0 ± 12.85
B
Control	100.0 ± 29.9
Lu AA33810	142.4 ± 44.3
U0126	150.3 ± 48.88
Lu AA33810+U0126	121.0 ± 28.75
LY294002	69.36 ± 14.48
Lu AA33810+LY294002	103.1 ± 64.26

The time schedule for the effect of L-AAA, Lu AA33810, and inhibitors is adequate to that used in the FST. The doses of the used compounds are L-AAA (twice at a dose of 100 μg/2 μl), Lu AA33810 (10 mg/kg, i.p.), U0126 (5 μg/2 μl/rat, i.c.v.), and LY294002 (10 nmol/2 μl/rat, i.c.v.). The values represent the mean ± SEM (n = 8–16 rats per group) and were evaluated by two-way ANOVA, followed by the Bonferroni multiple comparison test